{
Editas Medicine, Inc.

Companies

}
Symbol EDIT
Name Editas Medicine, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State MA
City Cambridge
Zipcode 2141
Website http://www.editasmedicine.com
Track all markets on TradingView
editas medicine lays off staff and shifts focus to in vivo gene editing
Editas Medicine will lay off 180 employees, about two-thirds of its workforce, as it shifts focus to “in vivo” gene editing after failing to find a partner for its sickle cell therapy. The company is ending development of its lead CRISPR medicine and will share more preclinical data in early 2025.
BioPharma Dive
United States Dollar bluebird bio, Inc. CRISPR Therapeutics AG Editas Medicine, Inc. Baisong Mei Gilmore O’Neill Show more
Technology & Innovation, News Article
01:00 12.12.2024
editas medicine reports quarterly loss and misses revenue expectations
Editas Medicine reported a Q3 loss of $0.75 per share, slightly better than the expected loss of $0.76, but revenues plummeted to $0.06 million, missing estimates by 99.13%. The company has seen a 71.3% decline in shares this year, with a current Zacks Rank of #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions, with current consensus estimates at -$0.67 EPS and $13.31 million in revenues for the next quarter.
Yahoo Finance
Editas Medicine, Inc. USA
Finance & Economy, Market Report
14:40 04.11.2024
editas seeks partner for gene editing therapy amid strategic shift
Editas Medicine is seeking a partner or considering out-licensing its lead gene editing therapy, reni-cel, aimed at treating sickle cell disease and beta thalassemia. This shift comes as the company pivots from previous strategies and aims to reduce spending while advancing its research. Despite promising preclinical data, Editas faces challenges in bringing reni-cel to market, prompting a focus on in vivo gene editing for future treatments.
BioPharma Dive
United States Dollar Moelis & Company Vertex Pharmaceuticals Incorporated Genevant Sciences CRISPR Therapeutics AG Editas Medicine, Inc. USA Gilmore O’Neill Dae Gon Ha Show more
Healthcare, News Article
17:15 22.10.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Corporate Responsibility & ESG Market Sentiment Analysis Central Bank Actions Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Banking Regulations Tokenomics and Crypto Economics Cryptocurrency Regulations Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Funding Rounds & Investments Mergers & Acquisitions Cryptocurrency Developments SEC & Financial Compliance Inflation Rates & CPI Data Real Estate Investments Shareholder Activism
Countries:
USA CHE JPN AUS CAN IND GBR DEU AUT CHN HKG RUS LIE SAU BHR FRA ARG COL FIN NLD
Companies:
Coinbase Global, Inc. Ripples USD Solana USD BlackRock, Inc. Ethereum USD Credit Suisse Real Estate Fund Siat NVIDIA Corporation Cardano USD Tesla, Inc. Apple Inc. MicroStrategy Incorporated Amazon.com, Inc. Sumitomo Corp Google Inc. Bitwise Bitcoin ETF Chainlink USD Palantir Technologies Inc. Tether USDt CNY VAT Group AG Northern Star Resources Ltd
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee
People:
Ali Martinez Donald Trump Michael J. Saylor Elon Musk Karin Keller-Sutter Charles Hoskinson Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Gary Gensler Ueli Maurer Mario Nawfal Alan Santana Richard Schueler Roger J. Hamilton Steven Rossi Jane Dietze

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.